Life sciences lead first-quarter growth in VC financing [pg. 15]

Financing reached $133 million from January through March.

By SHARON WROBEL
April 13, 2006 00:38
1 minute read.
Life sciences lead first-quarter growth in VC financing [pg. 15]

microscope 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Venture capital financing in Israel's life sciences sector more than doubled in the first quarter, surpassing the traditionally strongest area of communications technology. According to Leap Capital's Israel Tech and VC Review for the quarter, VC financing in life sciences reached $133 million from January through March, compared with $62m. during the average quarter of 2005. The traditionally strong sectors all also saw increased levels of VC financing activity, but nowhere near the levels seen by biotechnology: communications grew by 20 percent to $98m., while software rose 99% to $63m. and semiconductors by 3% to $28m. Israel's life sciences sector accounted for more than 40% of VC private financing of Israeli tech companies, led by a $90m. investment by TA Associates in Alma Lasers, an aesthetic medical lasers company. Total VC investment activity, involving 38 transactions was $331m., representing an increase of 64% over the first quarter of 2005, the report said. Israeli companies raised a total of $1.7 billion on the capital markets during the first quarter, of which $1.5b. were from life sciences public financings. M&A activity totaled $705m., down from the $3b. average per quarter due to the lack of big volume transactions. Out of the 11 transactions in M&A, 44% were in life sciences. The quarter also saw continued increased participation of foreign VC and tech finance firms in Israel. New Israel initiatives launched during the first quarter included venture lending firm Lighthouse Capital Partners, investment banks Goldman Sachs and WR Hambrecht, and VC Lightspeed Venture Partners forming a joint Internet Lab project with local VC Gemini Israel Funds. Foreign buying of Israeli tech companies during the same quarter included Sun Microsystems acquiring Aduva; BMC Software buying Identify Software; Johnson & Johnson purchasing ColBar; and VeriSign buying Snapcentric. The most active VCs in Israel during the first quarter of 2006 were Carmel Ventures and Intel Capital with four investments each, while Lightspeed Venture Partners, Ofer Hi-Tech, Pitango, Star Ventures and Vertex each made three investments during the quarter, Leap said. IPO activity was weak in the first quarter with two reported offerings between Nasdaq and London's Aim market. Strong IPO activity is expected in the second quarter with six public offerings waiting in the registration pipeline - five on Nasdaq and one on Aim.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS